Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.55 – $2.25
17% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $281.4K | $493.6K | $577.3K | $529.9K | $895.5K | $894.0K | $537.1K |
| Cost of revenue | $342.7K | $370.5K | $399.7K | $347.7K | $385.8K | $319.1K | $763.0K |
| Gross profit | −$61.3K | $123.1K | $177.6K | $182.2K | $509.7K | $574.9K | −$225.9K |
| Gross margin | -21.8% | 24.9% | 30.8% | 34.4% | 56.9% | 64.3% | -42.1% |
| R&D | $250.3K | $311.9K | $466.7K | $3.7M | $9.6M | $5.8M | $4.9M |
| Operating income | −$921.9K | −$766.1K | −$9.7M | −$26.4M | −$26.6M | −$18.7M | −$13.5M |
| EBITDA | −$702.1K | −$257.6K | −$11.3M | −$25.7M | −$25.0M | −$19.6M | −$12.9M |
| Net income | −$957.1K | −$586.9K | −$11.7M | −$26.5M | −$26.3M | −$21.7M | −$16.2M |
| Net margin | -340.1% | -118.9% | -2024.8% | -4992.2% | -2936.5% | -2421.8% | -3018.3% |
| EPS (diluted) | -0.10 | -0.05 | -1.67 | -1.87 | -1.62 | -22.36 | -2.70 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $917745 | $-0.03 | $-0.03–$-0.03 | 1 |
| 2027 | $2M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2028 | $30M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2029 | $74M | $-0.04 | $-0.04–$-0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds MYNZ.
No tracked institution reports a position in MYNZ as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-12-03 | 1-for-40reverse |
No one on the platform has traded MYNZ yet.
| $4M |
| — |
| GBSGBS Inc. | $0.47 | -1.58% | $433577 | — |
| HSCSHeartSciences Inc. | $2.75 | -6.46% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 9.7× sales vs its 3119.7× historical median P/S.
Fair value ≈ $271.84 · price $0.84 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.